Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma

C.L. Grosskreutz, R. Egan, E. Scigliano, S.M. Fruchtman, L.M. Isola
2004 Biology of Blood and Marrow Transplantation  
The time to ANC Ͼ500 ranged from 8 to 19 days with a median of 10 days. The median length of stay was 21 days. Three patients experienced early treatment-related mortality. With median follow up of 21 months, 45 patients have relapsed. The five year disease free survival (DFS) is 26% and overall survival (OS) is 58%. Thirty-nine patients (44%) remain alive and disease free. There was no difference in DFS (P ϭ .82)or OS (p ϭ .55) between those patients who received 4 cycles of VAD compared to
more » ... se who received any other number of VAD cycles. There appears to be no advantage to giving anything more than 4 cycles of VAD before proceeding to stem cell transplant.
doi:10.1016/j.bbmt.2003.12.092 fatcat:xl5fdoxg2ndu7pqiqinl2sih3m